Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | TP53 |
Variant | R267P |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | TP53 R267P lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). R267P results in impaired transcriptional activation of CCNA2 and CHEK1 (PMID: 28394262), but partially retains transcriptional activation of AXL and p21 in cell culture, leads to increased cell proliferation in culture but suppresses tumor formation in animal models (PMID: 22989750), and therefore, its effect on Tp53 protein function is unknown. |
Associated Drug Resistance | |
Category Variants Paths |
TP53 mutant TP53 exon8 TP53 R267P |
Transcript | NM_000546.6 |
gDNA | chr17:g.7673820C>G |
cDNA | c.800G>C |
Protein | p.R267P |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001126114.2 | chr17:g.7673820C>G | c.800G>C | p.R267P | RefSeq | GRCh38/hg38 |
NM_000546.6 | chr17:g.7673820C>G | c.800G>C | p.R267P | RefSeq | GRCh38/hg38 |
NM_001407271.1 | chr17:g.7673703C>G | c.800G>C | p.R267P | RefSeq | GRCh38/hg38 |
NM_001276761.3 | chr17:g.7673703C>G | c.800G>C | p.R267P | RefSeq | GRCh38/hg38 |
NM_001407267.1 | chr17:g.7673703C>G | c.800G>C | p.R267P | RefSeq | GRCh38/hg38 |
NM_001126113.2 | chr17:g.7673820C>G | c.800G>C | p.R267P | RefSeq | GRCh38/hg38 |
NM_001126114.3 | chr17:g.7673820C>G | c.800G>C | p.R267P | RefSeq | GRCh38/hg38 |
NM_001126112.2 | chr17:g.7673820C>G | c.800G>C | p.R267P | RefSeq | GRCh38/hg38 |
NM_001126113.3 | chr17:g.7673820C>G | c.800G>C | p.R267P | RefSeq | GRCh38/hg38 |
NM_001126118.2 | chr17:g.7673703C>G | c.800G>C | p.R267P | RefSeq | GRCh38/hg38 |
NM_001407270.1 | chr17:g.7673820C>G | c.800G>C | p.R267P | RefSeq | GRCh38/hg38 |
NM_001126112.3 | chr17:g.7673820C>G | c.800G>C | p.R267P | RefSeq | GRCh38/hg38 |
NM_001407266.1 | chr17:g.7673820C>G | c.800G>C | p.R267P | RefSeq | GRCh38/hg38 |
NM_001276695.3 | chr17:g.7673703C>G | c.800G>C | p.R267P | RefSeq | GRCh38/hg38 |
NM_001276696.3 | chr17:g.7673703C>G | c.800G>C | p.R267P | RefSeq | GRCh38/hg38 |
NM_001407263.1 | chr17:g.7673703C>G | c.800G>C | p.R267P | RefSeq | GRCh38/hg38 |
NM_000546.5 | chr17:g.7673820C>G | c.800G>C | p.R267P | RefSeq | GRCh38/hg38 |
NM_001407262.1 | chr17:g.7673820C>G | c.800G>C | p.R267P | RefSeq | GRCh38/hg38 |
NM_001407265.1 | chr17:g.7673703C>G | c.800G>C | p.R267P | RefSeq | GRCh38/hg38 |
NM_001407269.1 | chr17:g.7673703C>G | c.800G>C | p.R267P | RefSeq | GRCh38/hg38 |
NM_001407264.1 | chr17:g.7673820C>G | c.800G>C | p.R267P | RefSeq | GRCh38/hg38 |
NM_001407268.1 | chr17:g.7673820C>G | c.800G>C | p.R267P | RefSeq | GRCh38/hg38 |
NM_001276760.3 | chr17:g.7673703C>G | c.800G>C | p.R267P | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|